Skip to main content
. 2018 Oct 18;19(10):3226. doi: 10.3390/ijms19103226

Figure 9.

Figure 9

Loss of cardioprotective effect mediated by NOS and increase in infarct size with intraperitoneal injection of NOS-inhibitor (l-NAME), infarct size expressed in (%). Comparing Control (Saline, n = 12) and Sitagliptin (Sitg (50 mg), n = 10) groups shows a significant decrease in infarct size (*** p < 0.001), while this protective effect was abolished comparing the Sitg (50 mg) + l-NAME (Sitagliptin 50 mg + Nω-Nitro-l-arginine methyl ester hydrochloride (i.p), n = 11) group with the Sitg (50 mg, n = 10) treated group (# p < 0.05), which means that cardioprotective effect of Sitagliptin against infarction is mediated through NOS. A significant decrease († p < 0.05) in infarct size was also observed in Control (Saline) + l-NAME (Saline + Nω-Nitro-l-arginine methyl ester hydrochloride (i.p), n = 11) group, compared to Control (Saline). Data plotted as (Mean ± SEM).